Search

Liver failure is a common clinical syndrome with rapid progression and poor prognosis. Currently, there are still limited internal medical treatment methods for liver failure, and artificial liver support therapy is an effective treatment method. Nonbioartificial liver technology is widely used in clinical practice, and clinicians should determine the starting time, mode, and specific parameters of treatment according to the pathophysiological mechanism and dynamic evolution process of the disease, as well as the specific conditions of patients. Compared with non-bioartificial liver, biological artificial liver can better simulate the biological function of liver cells. At present, substantial progress has been made in its core technology, and related clinical studies are being conducted actively, suggesting a vast potential for future development. This article summarizes and discusses the optimization of non-bioartificial liver technology and the advances in biological artificial liver, in order to provide a reference for the clinical application and research of artificial liver technology. [ABSTRACT FROM AUTHOR]

Copyright of Tianjin Medical Journal is the property of Tianjin Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

ObjectiveTo investigate the influence of different durations of plasma diafiltration (PDF) on liver function in patients with liver failure and rebound of liver function after treatment. MethodsA total of 101 patients with liver failure who were admitted to Beijing YouAn Hospital, Capital Medical University, from January 2015 to December 2016 were enrolled, and according to the duration of treatment, these patients were divided into 4-hour group with 77 patients and 6-hour group with 24 patients. All patients were given artificial extracorporeal liver support therapy in addition to the medical treatment. The two groups were observed in terms of the reductions in alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), and direct bilirubin (DBil) after treatment and the rebound of ALT, AST, TBil, and DBil at 24 and 72 hours after treatment. The t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. ResultsAll patients had stable hemodynamics during treatment and no patient experienced adverse events. Some patients complained of staying in bed for a long time and feeling weak. The 6-hour group had a significantly higher intolerance rate than the 4-hour group ［41.7% (10/24) vs 6.5% (5/77), χ2=17.90, P＜0.01］. There were no significant differences in the reductions in ALT, AST, TBil, and DBil after PDF treatment between the two groups (t=2.53, -4.48, -1.52, and -0.47, all P＞0.05). There were also no significant differences between the two groups in the degrees of rebound of ALT, AST, TBil, and DBil at 24 and 72 hours after treatment (24 hours: t=-0.236, -1.251, -1.251, and 0.943, all P＞0.05; 72 hours: t=-0.700, 0.596, -1.530, and 1.837, all P＞0.05). ConclusionPDF treatment with different durations has similar effect and safety. Therefore, 4-hour PDF can be applied in clinical practice to improve patients′ tolerance. [ABSTRACT FROM AUTHOR]